title: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
abstract: BAY 59-7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous thrombosis. BAY 59-7939 competitively inhibits human FXa (K(i) 0.4 nm) with > 10 000-fold greater selectivity than for other serine proteases; it also inhibited prothrombinase activity (IC(50) 2.1 nm). BAY 59-7939 inhibited endogenous FXa more potently in human and rabbit plasma (IC(50) 21 nm) than rat plasma (IC(50) 290 nm). It demonstrated anticoagulant effects in human plasma, doubling prothrombin time (PT) and activated partial thromboplastin time at 0.23 and 0.69 microm, respectively. In vivo, BAY 59-7939 reduced venous thrombosis (fibrin-rich, platelet-poor thrombi) dose dependently (ED(50) 0.1 mg kg(-1) i.v.) in a rat venous stasis model. BAY 59-7939 reduced arterial (fibrin- and platelet-rich) thrombus formation in an arteriovenous (AV) shunt in rats (ED(50) 5.0 mg kg(-1) p.o.) and rabbits (ED(50) 0.6 mg kg(-1) p.o.). Slight inhibition of FXa (32% at ED(50)) reduced thrombus formation in the venous model; to affect arterial thrombosis in the rat and rabbit, stronger inhibition of FXa (74%, 92% at ED(50)) was required. Calculated plasma levels in rabbits at the ED(50) were 14-fold lower than in the rat AV shunt model, correlating with the 14-fold lower IC(50) of FXa inhibition in rabbit compared with rat plasma; this may suggest a correlation between FXa inhibition and antithrombotic activity. Bleeding times in rats and rabbits were not significantly affected at antithrombotic doses (3 mg kg(-1) p.o., AV shunt). Based on these results, BAY 59-7939 was selected for clinical development.
authors.affiliation: Cardiovascular Research, Bayer HealthCare AG, Wuppertal, Germany. perzborn@bayerhealthcare
authors.forename: E
authors.initials: E
authors.lastname: Perzborn
authors.forename: J
authors.initials: J
authors.lastname: Strassburger
authors.forename: A
authors.initials: A
authors.lastname: Wilmen
authors.forename: J
authors.initials: J
authors.lastname: Pohlmann
authors.forename: S
authors.initials: S
authors.lastname: Roehrig
authors.forename: K-H
authors.initials: KH
authors.lastname: Schlemmer
authors.forename: A
authors.initials: A
authors.lastname: Straub
mesh_terms: D000818:Animals; D001780:Blood Coagulation Tests; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D020128:Inhibitory Concentration 50; D009025:Morpholines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D000069552:Rivaroxaban; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013045:Species Specificity; D013876:Thiophenes; D013925:Thromboplastin / Q000378:metabolism; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D015842:Serine Proteinase Inhibitors; D013876:Thiophenes; D013925:Thromboplastin; D000069552:Rivaroxaban